The NCCN guidelines [1] define borderline pancreatic cancer for two locations: pancreatic head/uncinate process with CHA or SMA involvement and pancreatic body/tail with CA involvement (Fig. 9). This evidence concerns the gene SMN1 and familial pancreatic carcinoma.